Resiquimod is a compound belonging to the imidazoquinoline family of compounds known to signal through Toll-like receptor 7. Resiquimod treatment has been demonstrated to inhibit the development of allergen induced asthma in experimental models. The aim of the present study was to elucidate the molecular processes that were altered following resiquimod treatment and allergen challenge in a mouse model of allergic asthma. Employing microarray analysis, we have characterized the "asthmatic" transcriptome of the lungs of A/J and C57BL/6 mice and determined that it includes genes involved in the control of cell cycle progression, the complement and coagulation cascades, and chemokine signaling. Our results demonstrated that resiquimod treatment resulted in the normalization of the expression of genes involved with airway remodeling, and generally, chemokine signaling. Resiquimod treatment also altered the expression of cell adhesion molecules, and molecules involved in natural killer (NK) cell-mediated cytotoxicity. Furthermore, we have demonstrated that systemic resiquimod administration resulted in the recruitment of NK cells to the lungs and livers of the mice, although no causal relationship between NK cell recruitment and treatment efficacy was found. Overall, our findings identified several genes, important in the development of asthma pathology, that were normalized following resiquimod treatment, thus improving our understanding of the molecular consequences of resiquimod treatment in the lung milieu. The recruitment of NK cells to the lungs may also have application in the treatment of virally induced asthma exacerbations. S28463; R-848; Toll-like receptor 7; microarray ASTHMA IS A DISEASE OF THE respiratory system, characterized by intermittent reversible airway obstruction, that is estimated to affect 300 million worldwide and results in a quarter million deaths annually (56). While the airflow obstruction in asthma results from contraction of airway smooth muscles (ASM), the underlying pathology in asthmatic airways is inflammatory in nature. In allergic asthma the inflammatory reaction is typically driven by the IgE-mediated recognition of environmental allergens resulting in the production of Th2 cytokines. These cytokines, in turn, participate in the recruitment of inflammatory cells such as CD4 ϩ T cells, mast cells, and especially eosinophils, to the airways (28).
ASTHMA IS A DISEASE OF THE respiratory system, characterized by intermittent reversible airway obstruction, that is estimated to affect 300 million worldwide and results in a quarter million deaths annually (56) . While the airflow obstruction in asthma results from contraction of airway smooth muscles (ASM), the underlying pathology in asthmatic airways is inflammatory in nature. In allergic asthma the inflammatory reaction is typically driven by the IgE-mediated recognition of environmental allergens resulting in the production of Th2 cytokines. These cytokines, in turn, participate in the recruitment of inflammatory cells such as CD4 ϩ T cells, mast cells, and especially eosinophils, to the airways (28) .
Toll-like receptors (TLR) belong to a family of conserved pathogen-associated molecular pattern recognizing receptors involved in the activation of innate and adaptive immune responses (86) . Each member of the TLR family (or combinations of two distinct TLR molecules) recognizes molecules derived from different pathogens; for example TLR4 recognizes lipopolysaccharides from gram-negative bacteria and TLR3 recognizes double-stranded RNA molecules produced by some viruses during replication. The interaction between TLR ligands and the TLRs on innate immune cells, such as dendritic cells, leads to cellular activation and the production of cytokines resulting in a Th1 or Th2 polarized adaptive response (1, 15, 77) . TLR expression and signaling also occur in nonimmune cells, such as airway epithelial and smooth muscle cells, where it again results in cytokine production (4, 45, 79) . Furthermore, several studies have demonstrated that TLR ligands are capable of modulating the expression of several asthmatic phenotypes (10) .
Resiquimod (R-848, S-28463) belongs to the imidazoquinoline family of compounds and is known to signal, in an MyD88-dependent manner, through TLR7 in mice (26) , and TLR7 and TLR8 in humans (35) . The natural ligands for these TLRs are single-stranded RNA molecules of viral origin (14, 25, 51) , and, as might be expected based on this fact, TLR7/8 and their ligands in vitro (91) and in animal models (23, 82) contribute to viral resistance through the production of type I interferons and Th1 cytokines including IL-12 (92) .
A fundamental mechanism that underlies allergic asthma pathology is a Th2-skewed immune response. The use of TLR7/8 ligands in the treatment of asthma and in particular the use of resiquimod, which is both more potent and water soluble than many other TLR7 or TLR8 ligands, have been investigated by several groups (11, 59, 60, 70, 78, 96 ) because these ligands have been shown to promote the development of Th1-skewed immune responses both in vitro (17, 19, 89, 91) and in vivo (89, 92) . Studies in models of allergic asthma in mice (60, 70, 78) demonstrated that resiquimod treatment during or after antigen sensitization could prevent the development of airway inflammation and hyperresponsiveness, as well as IgE and mucus production. Furthermore, resiquimod treatment also prevented the development of airway remodeling, in a chronic asthma model in the rat (11) , as assessed by ASM mass and goblet cell hyperplasia.
Despite the demonstration that resiquimod treatment is effective in preventing the development of allergic asthma in rodent models, the molecular and cellular consequences of this treatment remain poorly characterized. Ex vivo resiquimod treatment of human Th2 cells was able to stimulate IFN-␥ production (9) , and in BALB/c models of allergic asthma, both pulmonary IFN-␥ (70) and IL-12 (78) were found to be induced following systemic resiquimod treatment. Again in BALB/c mice, resiquimod treatment was found to be partially effective in IL-12p35 Ϫ/Ϫ mice unless IL-10 was simultaneously ablated (78) , in which case treatment had no effect. Furthermore, in vitro studies of human peripheral blood mononuclear cells (18) and mouse splenocytes (80) indicate that IgE production can be inhibited by resiquimod treatment in an (at least partially) IFN-␥-or IL-12-dependent manner. However, neither IFN-␥ nor IL-12 was found to be increased in the lungs of similarly treated A/J or C57BL/6 mice. In fact, in the lungs of both A/J and C57BL/6 mice (60) and Brown Norway rats (11) , IFN-␥ levels were lower in treated animals and the treatment appeared to have systemic anti-inflammatory effects. While methodological differences between these studies may in large part explain the differences in Th1 cytokine modulation, all the studies demonstrated significant drops in Th2 cytokine levels in the lungs of treated animals.
Given the dramatic and positive effects of resiquimod treatment on the development of phenotypes associated with allergic asthma and the relative paucity of data regarding the mechanism by which these effects are mediated, the aim of the present study was to elucidate the cellular and molecular processes that are altered following resiquimod treatment and antigen challenge in a mouse model of allergic asthma. To evaluate the changes in pulmonary gene expression resulting from resiquimod treatment in the context of a previously described model of allergic asthma in both A/J and C57BL/6 mice (60), we employed microarray analysis to identify the molecular pathways altered by resiquimod treatment.
MATERIALS AND METHODS

Antigen sensitization and challenge and drug treatment protocol.
A/J and C57BL/6 mice underwent an antigen sensitization, challenge, and drug treatment protocol as previously described (60) . In brief, animals were sensitized to ovalbumin (grade VI, Sigma) by three weekly intraperitoneal injections of ovalbumin in Imject Alum (Pierce). One week after the final sensitization injection, mice received either a 1% ovalbumin aerosol challenge (OVA, and RES) or a mock challenge (PBS) with a PBS aerosol, every 24 h for three consecutive days. One group of mice (RES) received 100 g of resiquimod (in 0.2 ml of PBS by intraperitoneal injection) 1 day prior to each antigen challenge. All procedures were reviewed and approved by the Montreal General Hospital and McGill University Animal Care Committees in accordance with the guidelines of the Canadian Council on Animal Care.
Microarray analysis. A/J and C57BL/6 mice (3 mice from each experimental group) were euthanized 3 h after the final antigen aerosol challenge, at which point the whole lungs were dissected and immediately frozen in liquid nitrogen. Total lung RNA was extracted and purified with TRIzol (Invitrogen) according to the manufacturer's instructions and subsequently used with Affymetrix Mouse430 v. 2.0 microarrays. The preparation of probes, the hybridization, and the scanning of the microarrays were performed at the McGill University and Génome Québec Innovation Centre according to the manufacturer's instructions.
Background correction and normalization were performed in the R environment (version 2.4.1, www.r-project.org) with the Bioconductor packages (version 1.12.2, www.bioconductor.org) using the robust multiarray average method (RMA) (31) of the affy package. Differential expression analysis was performed using the LIMMA package (83) (version 2.9.13). The data were encoded in a design matrix with all six strain/treatment combinations [A/J (PBS, OVA, and RES) and C57BL/6 (PBS, OVA, and RES)] and then fitted to a linear model. We then first analyzed the data by making pairwise comparisons between the two strains for each treatment, between the PBS and OVA treatment groups for each strain separately, and between the OVA and RES treatment groups for each strain separately. The effects of ovalbumin challenge (PBS vs. OVA) and resiquimod treatment (OVA vs. RES) were then analyzed jointly in both strains by using the contrast representing the mean of the expression differences, between the treatment groups, of each strain. In all cases a multiple test correction was then performed by the Benjamini-Yekuteli method (5) of the LIMMA package (83) , and finally, significant (at a false discovery rate ϭ 0.05) genes were then filtered for a minimum expression fold difference of 1.5 (in the joint analysis, a minimum 1.5-fold difference in each of the strains). All microarray data have been deposited in the Gene Expression Omnibus database (http:// www.ncbi.nlm.nih.gov/projects/geo/) under the accession number GSE13032.
Pathway analysis of genes identified as significantly altered between experimental groups was performed with EASE (29) . Overrepresentation of significant genes, among the population of genes that were present on the microarray, in Kyoto Encyclopedia of Genes and Genomes pathways (KEGG, www.genome.jp/kegg/) (36), was assessed using the EASE score and corrected for multiple testing by bootstrapping (1 ϫ 10 4 iterations) all probabilities. A pathway was considered significantly overrepresented if, after multiple testing correction, P Յ 0.05.
Fold changes used throughout this article represent the mean ratio of gene expression in the high expressing group to the low expressing group (the mean of the gene expression ratio of each strain). In comparisons of the sham-challenged (PBS) group to the untreated control group (OVA), positive fold change values indicate that the OVA group is the high expressing group and negative values signify that the PBS group is the high expressing group. Similarly, for comparisons involving the untreated control group (OVA) and the resiquimod-treated group (RES), positive values represent higher expression in the RES group and negative values represent higher expression in the OVA group. In all cases, the median fold change value of all significantly altered probe sets of any given gene is reported.
One outlier in the data was the 130-fold difference in expression of H2-D1 between A/J and C57BL/6 mice. The unusually large difference in H2-D1 appears to be caused by a pair of probe sets (1427651_x_at and 1452544_x_at) whose target sequence in the H2-D1 gene contains a pair of polymorphic single nucleotide polymorphism (SNPs, between A/J and C57BL/6). These probe sets were removed and not used in the subsequent analysis of strain differences. Of the next 45 genes with the largest absolute difference in expression between the strains, only one gene contained an SNP in the target sequence covered by a probe set. This SNP affected only one of the 11 probes within one probe set for this gene. Overall, this indicates that polymorphisms account for only a very small portion of the differences in expression between the strains and can generally be safely ignored.
Real-time RT-QPCR validation of microarray data. In an independent experiment, A/J mice were sensitized, challenged, and treated in an identical manner to the animals on which the microarray analysis was performed. The lungs of the experimental animals were snapfrozen in liquid nitrogen 3 h after the final antigen aerosol challenge and homogenized in TRIzol reagent (Invitrogen) for RNA isolation. Reverse transcription was performed using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's recommendations. Quantitative PCR was performed using the Brilliant QPCR SYBR Green QPCR Master Mix kit (Stratagene) on the Mx4000 apparatus (Stratagene) with the following cycling conditions: denaturation 30 s at 95°C, annealing 60 s at 56°C, and extension for 30 s at 72°C. Supplemental Table S1 lists the primers used in the analysis. 1 Flow cytometry analysis. A/J, C57BL/6 and B6.129S2-Cd8a tm1Mak /J (CD8 knockout mice backcrossed 13 generations to C57BL/6) mice were euthanized 3 h following the final antigen aerosol challenge, as described above, to confirm natural killer (NK) cell recruitment following resiquimod treatment in the asthma model, and for the NK cell depletion experiments described below. C57BL/6 mice were euthanized without antigen sensitization or challenge prior to receiving resiquimod, 3 h after receiving the first, second, or third daily resiquimod dose, or 24, 48, or 96 h following the third resiquimod dose to determine the effects of resiquimod treatment on NK cell recruitment. In all cases the lungs and livers were removed, placed in media, and finely cut with a scalpel blade. The finely cut pieces were placed in a digestion buffer containing 2 mg/ml of collagenase 4 and 10 g/ml of DNase (Worthington Biochemical) then incubated for 1 h at 37°C with continuous mixing. The resulting cell suspension was decanted and lymphocytes were extracted with Lympholyte M (Cedarlane Laboratories) according to the manufacturer's instructions.
The cells were then washed and resuspended in PBS. Cells were preincubated with rat anti-mouse CD16/CD32 (Fc␥ III/II Receptor) (clone 2.4G2, BD Biosciences) and then double-stained with phycoerythrin-conjugated rat anti-mouse CD49b (clone DX5, BD Biosciences) and fluorescein isothiocyanate-conjugated rat anti-mouse CD11b (clone M1/70, BD Biosciences). The cells were subsequently analyzed using a FACScan (BD Biosciences) machine. Cell counts were gated for lymphocytes based on front and side scatter, and NK cells were identified as gated CD49b and CD11b double-positive cells.
NK cell depletion. NK cell depletion was accomplished by intraperitoneal injection of 100 g of anti-NK-1.1 antibody (clone PK136, BioExpress Cell Culture Services) in a total volume of 200 l of PBS. The injection was carried out 24 h prior to the first resiquimod treatment (as described above). NK cell depletion efficiency was assessed by FACS analysis, as described below, and was found to result in a Ͼ90% depletion of NK cells in the lungs of the mice (Supplemental Fig. S1 ).
Bronchoalveolar lavage fluid analysis. Upon euthanasia, 48 h following the final antigen challenge, a blunt 18 G needle was inserted into the trachea of the animal. The lungs were then lavaged with 1.2 ml of PBS (Invitrogen), which was subsequently kept on ice. The lavage fluid was then centrifuged at 250 g; the cell pellet was resuspended in 100 l of RPMI medium (Invitrogen) and loaded into a cytospin centrifuge that was used to spin (at 350 rpm) the cells onto glass slides (Shandon Cytoslide, Thermo Scientific). The slides were fixed and stained with the DiffQuik stain set (Dade Behring), and a differential count was performed by a blinded observer.
Other statistical analysis. All flow cytometry, bronchoalveolar lavage fluid (BALF) cell counts, and RT-QPCR data were analyzed with a one-way ANOVA followed by a Bonferroni posttest. For BALF cell analysis, outliers that were more than two standard deviations above or below the mean were discarded. All data are expressed as means Ϯ SE.
RESULTS
Identification of genes differentially expressed between A/J and C57BL/6 mice. To evaluate the transcriptional differences induced by resiquimod treatment in antigen-sensitized and challenged mice we performed a microarray analysis on the whole lung RNA of both A/J and C57BL/6 mice following antigen sensitization and mock challenge (PBS), antigen sensitization and challenge (OVA), or antigen sensitization and challenge with resiquimod treatment (RES). We have previously shown that, in these strains, this sensitization and challenge protocol results in the induction of asthmatic phenotypes and that the resiquimod treatment ablates these phenotypes (60) . For each treatment protocol, the lungs of three mice of each strain were collected 3 h following the last antigen (or sham) challenge and analyzed with Affymetrix Mouse430 v. 2.0 microarrays.
The first set of comparisons performed compared gene expression in the lungs of A/J mice to the expression in the lungs of C57BL/6 mice in each treatment group (PBS, OVA, and RES). To assess the significance of differences in gene expression, genes were first selected on the basis of a P value meeting the threshold for a 0.05 false discovery rate (as described in MATERIALS AND METHODS). In our data, the threshold P value was 1.91 ϫ 10 Ϫ4 when comparing A/J mice to C57BL/6 mice in the PBS group, 1.81 ϫ 10 Ϫ4 in the OVA group, and 2.97 ϫ 10 Ϫ4 in the RES group. Genes whose expression was significantly different were defined as those that met this P value cut-off and had an absolute fold change, between the groups being compared, of 1.5 or more.
Using these criteria, we found that the expression of 1,043, 1,053, and 1,483 genes was significantly different between the strains in the PBS, OVA, and RES groups, respectively (Fig. 1 , Supplemental Tables S2-S4). Of the 1,043 genes found to be differentially expressed in the PBS group, only 13% (136 genes) had significant differences in expression only in the PBS group, a large majority (63% or 654 genes) were differentially expressed in all treatment groups, and the remainder (24%) were differently expressed in two groups including PBS. Similarly, the majority of genes found to be differentially expressed in the OVA group (62% of the 1,053 genes) were differentially expressed in all three treatment groups. Furthermore, the majority of genes found to be differentially expressed between strains in more than one treatment group were differentially expressed by a similar ratio in all groups. It 1 The online version of this article contains supplemental material. Fig. 1 . Summary of the total numbers of differentially expressed genes. Venn diagram summarizing the number of genes on the microarrays with statistically significant differences in expression (as described in MATERIALS AND METHODS) between A/J and C57BL/6 mice in each treatment group. All mice were sensitized with ovalbumin (OVA). The PBS group received 3 daily mock aerosol challenges of phosphate-buffered saline (PBS). The OVA and resiquimod (RES) groups received 3 daily OVA aerosol challenges. The RES group was also treated with 100 g of resiquimod 24 h prior to each challenge. therefore appears that most of the initial differences in gene expression between the strains were maintained regardless of allergen challenge and resiquimod treatment.
The 1,043 genes that were differentially expressed in the PBS group are involved in a multitude of biological processes, and KEGG pathway overrepresentation analysis by EASE did not identify any significantly overrepresented pathways. On the other hand, a similar analysis of the 1,053 genes that were found to be differentially expressed in the OVA group identified two overrepresented pathways: antigen processing and presentation, and cytokine-cytokine receptor interaction (Table 1, Supplemental Table S5 ). Six of the eight genes in the antigen processing and presentation pathway are histocompatibility-2 genes, of which one was more highly expressed in A/J mice and five in C57BL/6 mice. The other two genes are Lgmn (a.k.a. AEP), a lysosomal protein involved in cathepsin L processing (54) with a role in extracellular matrix (ECM) remodeling in the kidneys (62) whose expression is higher in A/J mice, and Klrd1 (CD94) whose expression is higher in B6 mice and, as a dimer with Klrc1 (NKG2A), acts as an inhibitory receptor for NK cells. Genes in the cytokine-cytokine receptor pathway were evenly divided with respect to which strain had the highest level of expression. Most of these genes were chemokines with A/J mice having higher transcript levels for Ccl6, Ccl11 (eotaxin), Ccl24 (eotaxin-2), and Cxcl12 (SDF) and C57BL/6 mice for Ccl19 (MIP-3␤), Ccl21a (SLC), Ccl27 (CTACK), Cxcl7, and Cxcl14 (BRAK, MIP-2␣).
Most (60%) of the strain differences observed in the resiquimod treatment group were genes whose expression was also different in either the OVA or PBS groups. These genes also had the same differences in expression across the different treatments, indicating that most of these differences were unlikely to have been caused by resiquimod. However, a significantly larger fraction of the genes identified as differentially expressed in the RES group were found to be differentially expressed only in resiquimod-treated animals. In fact, a full 40% of the differently expressed genes in resiquimodtreated animals were only differentially expressed in these animals (vs. 13 and 15% for the PBS and OVA groups, respectively).
KEGG pathway analysis with EASE identified four significantly overrepresented pathways: antigen processing and presentation, cell adhesion molecules, type I diabetes mellitus, and NK cell-mediated cytotoxicity (Table 1, Supplemental Table  S6 ). The antigen processing and presentation pathway contains many of the same histocompatibility genes that were already differentially expressed after OVA treatment. Furthermore, the relative difference in expression of these genes between the strains is maintained at similar levels. Four additional histocompatibility genes (H2-Dma, H2-Q1, H2-Oa, and H2-Eb1) as well as the CD8 receptor (Cd8a and CD8b1) and the CD94/ NKG2A receptor (klrc1 and klrd1) genes had higher expression in C57BL/6 mice following resiquimod treatment. Of the 20 cell adhesion pathway genes, the same 10 histocompatibility genes and the CD8 receptor genes that were found in the antigen processing and presentation pathway were present. In addition, several genes involved in modulating cell adhesion (Itgb7, Itgal, Cd34, and Spn) were found to be expressed in the resiquimod-treated C57BL/6 mice at higher levels than in the A/J mice. However, this pathway also contained several claudin genes (Cldn7, 8, 10, 23) , a family of genes involved in the formation of tight junctions, which had higher transcript levels in the resiquimod treated A/J mice. The type I diabetes mellitus pathway contains the same 10 histocompatibility genes as the two other pathways along with granzyme B, a gene involved in cytotoxic T-cell and NK cell-mediated cytotoxicity. Finally, all the genes in the NK cell-mediated cytotoxicity pathway were expressed at higher levels in resiquimod-treated C57BL/6 mice than in A/J mice. The 17 genes belonging to this pathway and found to be differentially expressed between resiquimodtreated mice of the two strains include the CD94/NKG2A (klrc1 and Klrd1) genes and several other NK cell receptors (Klra3, Klrb1c, Klrk1, Klra7, Klra8, and Cd244), the integrin Itgal, the antibody receptors Fcgr3a and Fcer1g, genes involved in signal transduction (Tyrobp, Sh2d1a, Pik3r4, and Nfatc1), the histocompatibility gene H2-T23, and granzyme B.
Identification of genes differentially expressed following antigen challenge. Changes in gene expression resulting from antigen challenge (PBS group vs. OVA group) were then investigated. Differentially expressed genes were first identi- 
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The pathways listed are those contained in the KEGG (36) mouse pathway database that were significantly overrepresented after antigen challenge of sensitized animals (ovalbumin, OVA), or resiquimod treatment (RES), as assessed by EASE (29) (detailed in MATERIALS AND METHODS). The Hits column represents the number of genes with significant differences in expression, where significance was assessed as described in MATERIALS AND METHODS. The Assayed column represents the number of genes belonging to the pathway which were assayed by the Affymetrix Mouse 430v2 chips. The "A/J High" and "C57BL/6 High" columns represent the number of genes whose expression was higher in the A/J and C57BL/6 mice, respectively. The EASE score of each pathway is indicated. The threshold of significance was set at P Յ 0.05 after correction by the bootstrap method incorporated in EASE. Bootstrap P values are reported in the Bootstrap column.
fied in each strain separately, as described in MATERIALS AND METHODS. Ovalbumin challenge led to changes in expression of 268 genes in the A/J strain (Supplemental Table S7 ) and 148 genes in the C57BL/6 strain (Supplemental Table S8 ). Of these, 116 genes, or 39% of the combined list, were found to be differentially expressed independently in both strains. While the 32 genes whose expression was found to be altered only in C57BL/6 mice do not exhibit any clear pattern or groupings, two groups of genes are easily observable in the 152 genes that were only identified in the A/J strain ( Table 2 ). The first group includes a number of genes that may be involved in the regulation of the ECM and includes several procollagenase genes (Col1a1, Col1a2, Col3a1, Col5a2, and Col6a2), cathepsins (Ctsk, Ctss, Ctsk), tenascin (Tnc), and thrombospondin 1 (Thbs1), all of which were induced following OVA challenge. The second group consists of cytokines and cytokine receptors and includes interleukin-6 (Il6),the C-C chemokines Ccl6 and Ccl22, the C-X-C chemokine Cxcl12, BAFF (Tnfsf13b), as well as several receptors (Ccr1, Cx3cr1, Csf2rb1, Csf2rb2, and Tnfrsf9). With the exception of the fractalkine receptor (Cx3cr1), the cytokines and receptors were all found to be expressed at higher levels in OVA-challenged A/J mice than PBS-challenged A/J mice.
Given that the transcriptional changes induced by antigen challenge significantly overlapped in the two tested strains, and given that the experimentally induced allergic asthma that results from antigen challenge is similar in both strains, the data generated from both strains were analyzed jointly (as described in MATERIALS AND METHODS). This analysis identified 197 genes as differentially expressed following antigen challenge, of which 156 (79%) were previously identified employing only the A/J strain, 122 (62%) were identified employing only the C57BL/6 strain, 116 (59%) were identified in each strain independently, and 35 (18%) were not identified when employing only the A/J or only the C57BL/6 strain.
Using the pooled analysis incorporating data from both strains, the genes whose expression was significantly altered by antigen challenge were ranked based on the absolute value of the fold change in expression. The top 30 genes, in terms of absolute fold change, between the antigen-challenged and the sham-challenged lungs are listed in Table 3 . The direction of differential gene expression in the lungs of antigen-challenged mice compared with the sham-challenged mice is immediately apparent from Table 3 . Of the 30 genes with the largest fold change in expression, all were upregulated in the antigenchallenged mice. Furthermore, the extent of upregulation was important with 18 genes having a greater than fivefold increase in expression and 37 genes with a greater than threefold increase in expression. By comparison, of the seven genes that were downregulated after antigen challenge, only two had a greater than twofold change in expression (whereas 89 genes were upregulated by more than twofold).
An examination of the genes listed in Table 3 reveals the presence of eight chemokines (Ccl7, Ccl8, Ccl11, Ccl12, Ccl17, Ccl24, Cxcl9, and Cxcl10). Most of the other genes in the table have been associated with asthma. For example, Ear11 is an eosinophil-associated ribonuclease that has been observed in the lungs of asthmatic mice (13) , and Clca3 (Gob-5) has been shown to cause mucus overproduction and airway hyperresponsiveness in mice (63) .
To identify features in the data that were unlikely to be present by chance alone, EASE was used to identify pathways found in the KEGG in which differentially regulated genes were overrepresented. When the list of 197 genes whose expression was significantly altered following antigen challenge was analyzed with EASE, significantly altered genes were found to be overrep- 
Pathways contained in the KEGG (36) mouse pathway database that were significantly affected by antigen challenge of sensitized animals as assessed by EASE (29) as detailed in MATERIALS AND METHODS. The Hits column represents the number of genes significantly affected by treatment, relative to untreated controls, where significance was assessed as described in MATERIALS AND METHODS. The Assayed column represents the number of genes belonging to the pathway that were assayed by the Affymetrix Mouse 430v2 chips. The "A/J High" and "C57BL/6 High" columns represent the number of genes whose expression was higher in the A/J and C57BL/6 mice, respectively. The EASE score of each pathway is indicated. The threshold of significance was set at P Յ 0.05 after correction by the bootstrap method incorporated in EASE. Bootstrap P values are reported in the Bootstrap column.
resented in three pathways (Table 4) . In all three cases (cell cycle, cytokine-cytokine receptor interaction, and complement and coagulation cascades), all the differentially expressed genes in the pathway were upregulated (Supplementary Table S9) . Genes involved in cell cycle control and proliferation represent one of the largest groups to be upregulated in the asthmatic transcriptome and include the cyclins Ccna2, Ccnb1-rs1, Ccnb2, and Ccne2, and the cell division cycle genes Cdc2a, Cdc20, Cdca8, Mcm2, Mcm5, and Mcm6. All the differentially expressed genes in the cytokinecytokine receptor interaction pathway were chemokines and, in one case, a chemokine receptor.
Identification of genes differentially expressed following resiquimod treatment. The transcriptional consequences of resiquimod treatment in the context of the allergic asthma model were then explored. First, the strains were analyzed separately as described in MATERIALS AND METHODS. Using those criteria, we found the expression levels of 565 genes in the A/J mice (Supplemental Table S10 ) and 697 genes in the C57BL/6 mice (Supplemental Table S11 ) to be altered by resiquimod treatment. Of the combined set of genes, the expression of only 260, or 26%, were found to be altered in both strains independently. The genes that were only identified as differentially expressed in A/J mice were generally downregulated following resiquimod treatment (200 genes, or 66%) and represented a wide assortment of genes in which we identified no informative motifs (Supplemental Table S8 ). The 437 genes that were identified only in the C57BL/6 mice (Supplemental Table S9 ), however, were mostly upregulated (372 genes, or 85%) and contained several significantly overrepresented KEGG categories, namely, B cell receptor signaling pathway, NK cellmediated cytotoxicity, cell cycle, leukocyte transendothelial migration, and cell adhesion molecules (Table 4, Supplemental  Table S12 ).
Despite the fact that the two strains present important differences in their response to resiquimod treatment, this treatment is effective in preventing the development of experimental allergic asthma in both strains. This suggests that a joint analysis of both strains has the potential to reveal universal effects of resiquimod administration as well as its effect on asthma development. To this end, the data from both strains were pooled, and an analysis was performed (as described in MATERIALS AND METHODS), identifying 386 genes as differentially expressed following antigen challenge, of which 283 (73%) were identified as differentially expressed when the A/J strain was analyzed independently, 310 (80%) were identified as differentially expressed when the C57BL/6 strain was analyzed independently, 250 (65%) were identified as differentially expressed in each strain independently, and 43 (11%) were not identified when the strain were analyzed separately.
Using the pooled analysis, which incorporates data from both strains, we ranked the genes whose expression was significantly altered by resiquimod treatment based on the absolute value of the average fold change in expression of the two strains. In contrast to the genes listed in Table 3 , the 30 genes with the largest absolute fold changes in expression in the lungs of resiquimod-treated mice, compared with mice that had only been antigen-challenged, are evenly divided with respect to up-and downregulation (Table 5) . However, the magnitude of the changes in gene expression is similar with 28 genes whose expression was altered by more than fivefold (14 upregulated and 14 downregulated) and 69 genes with a greater than threefold change in expression (41 upregulated and 28 downregulated).
When the downregulated genes are examined, it can be observed that 10 of the 15 most downregulated genes (Ear11, Mgl2, Slc26a4, Chi3l4, Cd209e, Ccl24, Ccl17, Clca3, Fcgbp, and Ccl11) following resiquimod treatment were found to have been upregulated by antigen challenge alone (Table 5) . One of the most interesting features of the upregulated genes is that 7 of the 15 genes (Gzma, Gzmb, Prf1, Nkg7, Klra3, Klrd1, and Ncr1) are associated or involved with cell-mediated cytotoxicity or killer cell receptors. The remaining most highly up-and downregulated genes are involved in an assortment of known and unknown processes, and no clear features can readily be identified from a simple cursory inspection of the data.
EASE was again used to identify KEGG pathways in which differentially regulated genes were overrepresented. Significantly altered genes were found to be overrepresented in four pathways when the list of 386 genes, whose expression was significantly altered following resiquimod treatment, was analyzed (Table 4, Supplemental Table S13 ). All four of the pathways [NK cell-mediated cytotoxicity (NKCMC), cytokine-cytokine receptor interaction, Type I diabetes mellitus, and cell adhesion molecules (CAMS)] are related to immune function, and all four contain predominantly, or uniquely, upregulated genes. The cytokine-cytokine receptor interaction pathway, with seven downregulated genes, was the pathway with the most downregulated genes. All of these were chemokine genes (Ccl8, 11, 12, 17, 22 , and 24, and Cxcl12), which, with the exception of Ccl22 (MDC), were found to be induced by antigen challenge in the absence of resiquimod treatment (although even Ccl22 was significantly elevated in the A/J mice and nonsignificantly elevated in C57BL/6 mice).
By several orders of magnitude, the pathway in which differentially expressed genes are most significantly overrepresented (as assessed by the magnitude of the EASE score) is the NKCMC pathway. All differentially expressed genes in the NKCMC pathway were upregulated (Fig. 2) . In fact, the fold changes in Gzmb and Prf1 expression were the second and third largest fold changes, respectively, induced by resiquimod treatment, while the related gene Gzma, which is not listed in the KEGG NKCMC pathway, had the largest fold change. Overall, the magnitude of the changes in expression of the genes in the NKCMC pathway, in which eight and six of the 21 genes displayed a greater than three-and fivefold change in expression, respectively, 38 and 29%, was far greater than the magnitude of the changes in expression for the entire population of genes which were differentially expressed following resiquimod treatment. In the latter case, 69 (18%) and 28 (7%) of the 386 genes had a greater than three-and fivefold change in expression, respectively.
Real-time RT-QPCR validation of differentially expressed genes.
To validate the microarray expression measurements we performed real-time quantitative reverse transcriptase PCR on whole lung RNA samples obtained from an independent set of six A/J mice per experimental group. A total of 14 genes were selected that represented ϳ2-to 20-fold differences in expression between both the sham-challenged and antigen-challenged groups, and the antigen-challenged and resiquimod-treated groups. As can be observed in Fig. 3A , the expression changes of the nine genes whose expression was increased following antigen challenge and decreased following resiquimod treatment were confirmed. Furthermore, changes in the five genes 
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The pathways listed are those contained in the KEGG (36) mouse pathway database that were overrepresented by genes whose transcript levels were significantly affected by antigen challenge (OVA) or resiquimod treatment (RES) in the joint analysis of both the A/J and C57BL/6 strains, or that were significantly affected by resiquimod treatment in the C57BL/6 strain, but not the A/J strain, when the strains were analyzed separately. The Hits column represents the number of genes significantly affected by antigen challenge (OVA) or resiquimod treatment (RES) treatment, relative to nonchallenged controls (OVA) or untreated animals (RES), respectively. The significance of differences was assessed as described in MATERIALS AND METHODS. The Assayed column represents the number of genes belonging to the pathway that were assayed by the Affymetrix Mouse 430v2 chips. The Up and Down columns represent the number of genes that were induced and repressed, respectively. The EASE (29) score of each pathway is indicated. The threshold of significance was set at P Յ 0.05 after correction by the bootstrap method incorporated in EASE. Bootstrap P values are reported in the Bootstrap column. whose expression was induced following resiquimod treatment (Fig. 3B) were also confirmed.
Recruitment of NK cells following resiquimod treatment. To determine whether the increased expression of genes contained within the NKCMC pathway were the result of the recruitment of NK cells into the lungs of resiquimod-treated mice; we assessed the relative abundance of NK cells in the lungs of sham-challenged A/J mice as well as antigen-challenged mice with or without resiquimod treatment. The mice were euthanized, at the same time point that was used to generate the microarray data, 3 h following the final antigen challenge. Cells were then isolated from the lungs, as described in MATERIALS AND METHODS, and the relative number of NK cells was assessed. In antigen-sensitized animals, antigen aerosol challenge did not significantly alter the relative number of NK cells (Fig. 4 , OVA vs. PBS). However, NK cell numbers increased almost fivefold following resiquimod treatment (RES vs. OVA).
To confirm that the NK cell recruitment observed in the experimental asthma model was a result of resiquimod treatment alone, we evaluated the influx of NK cells following resiquimod treatment in the lungs of C57BL/6 mice (Fig. 5) . We observed that the proportion of NK cells trends upward as soon as 3 h following the first injection and is statistically significantly elevated 3 h after both the second and third doses (Fig. 5A) . These elevated lung NK cell levels remain relatively stable for 48 h after the last dose of resiquimod before starting to return to basal levels after 96 h (Fig. 5B) . To determine whether the influx of NK cells was specific to the lungs, NK cells were also assessed in the livers and spleens of the same animals. The NK cell levels in the liver, which increase following each dose of resiquimod, mirror those observed in the lungs of the same animals (Fig. 5A) . As in the lungs, NK cell levels peak between 3 and 24 h following the final resiquimod dose. However, NK cell levels in the livers fully returned to basal levels 96 h after the last dose and demonstrated a greater decline than that which was observed in the lungs after 48 h (Fig. 5B) .
Role of cytotoxic cells in resiquimod treatment of allergic asthma. The role of the recruited NK cells on the ability of resiquimod treatment to prevent the development of allergic asthma, as measured by the eosinophil content of BALF recovered 48 h following the final antigen challenge, was then assessed. As previously described (60) , antigen sensitization and challenge results in eosinophilic infiltration of the lungs. This infiltration can be observed in BALF and is prevented by 
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Differential gene expression in resiquimod-treated animals. The table contains the 30 transcripts showing the largest absolute fold change between resiquimod-treated and untreated animals following antigen challenge. All animals were sensitized to the antigen. Positive and negative fold changes represent up-and downregulation of genes, respectively, in treated mice versus untreated mice. Unadjusted P values are shown and only genes with significantly altered expression are included (statistical assessment is described in MATERIALS AND METHODS).
resiquimod treatment (Fig. 6A) . Anti-NK1.1 antibodies were used to deplete NK cells to determine if this effect could be observed in the absence of NK cells. Resiquimod treatment of antigen-challenged mice, despite NK cell depletion, prevented eosinophil recruitment (Fig. 6B) . Changes in airway responsiveness were also assessed; however, depletion of NK1.1 ϩ cells prevented the development of hyperresponsiveness, making it difficult to draw any further conclusions on the role of these cells in resiquimod treatment of allergic asthma in these mice (data not shown).
To determine whether the cytotoxic activity of cytotoxic T lymphocytes, rather than the cytotoxic activity of NK cells, is necessary in order for resiquimod treatment of allergic asthma to be effective, resiquimod treatment was assessed in Cd8 knockout mice. The absence of CD8 T cells did not reduce the effectiveness of resiquimod treatment as assessed by the eosinophilic content of the BALF (Fig. 6C) .
DISCUSSION
Two strains of mice were employed in our study. The A/J strain is considered asthma-susceptible (high airway responsiveness to methacholine and a predisposition toward the production of IgE antibodies), while the C57BL/6 strain is considered asthma-resistant (low airway responsiveness to methacholine and low IgE production). However, experimental allergic asthma can be induced in both strains and despite carrying different versions of the Slc11a1 gene (formerly Nramp1), which has been shown to modulate responsiveness to resiquimod treatment in a mycobacterium infection model (61) , both strains respond to resiquimod treatment in the context of asthma (60) .
After the lungs are challenged with the antigen, differences in gene expression emerge from which clear patterns can be observed. In particular, changes in antigen processing and Fig. 2 . Genes in the natural killer (NK) cell-mediated cytotoxicity pathway altered by RES treatment. Represented is a portion of the NK cell-mediated cytotoxicity pathway (04650mmu) adapted from the KEGG (36) database. The 21 genes contained within this portion of the pathway with significant changes in pulmonary expression, when resiquimod-treated mice were compared with untreated mice, are highlighted (yellow Յ3-fold, orange Յ6-fold, pink Յ9-fold, and red Ͼ9-fold increase in expression). The pathway contains a total of 128 genes, 110 of which were assayed, and 21 of which were significantly altered. All mice were antigen sensitized and challenged, and treated mice received 100 g of RES 24 h prior to each antigen challenge. Fold changes in gene expression are expressed as the ratio of expression in the RES-treated mice to the untreated asthmatic mice. The significance of changes in expression was determined as described in MATERIALS AND METHODS. presentation and in cytokine-cytokine receptor interactions are prominent. Interestingly, we see differences in chemokine expression where the A/J mice express asthma-associated Ccr3-binding chemokines highly, consistent with the more atopic phenotypes of the A/J mice. Furthermore, upregulation of genes involved in airway remodeling, such as procollagenases, cathepsins, and tenascin, were observed only in A/J mice, leading us to speculate that these genes may contribute to the more severe airway hyperresponsiveness phenotype observed in this strain (16) .
By identifying genes whose expression is consistently altered by the induction of experimental asthma in mice (either by OVA or Aspergillus fumigatus), a core and reproducible "asthmatic" transcriptome can be characterized. We have compared here the genes identified in our study, using an OVAinduced model in both A/J and C57BL/6 mice, to the genes identified by Zimmermann et al. (100) , using both an OVAand an A. fumigatus-induced model in BALB/c mice, as well as by Kuperman et al. (44) , using an OVA-induced model in BALB/c mice (summarized in Table 6 ).
Despite the use of different microarrays, statistical analyses, sensitization and challenge protocols, allergens, and strains of mice, there was significant overlap between the genes identified in all studies. Nearly half (42%, or 82 out of 197 genes) of the genes identified as significantly altered in the present study (OVA-induced model of asthma in both A/J and C57BL/6 mice) were also identified as significantly altered in both the A. fumigatus induced model of asthma and in at least one of the OVA-induced models in BALB/c mice (Supplemental Table  S14 ) (44, 100) . Furthermore, in every study, the overwhelming majority of genes with significantly altered expression, including those identified in only one or two studies, were upregulated.
Three groups of genes are prominent in this asthmatic transcriptome: genes involved with cell cycle control and progression, genes involved in the complement and coagulation cascades, and chemokines and their receptors. The activation of cell cycle control genes has been identified as a common lung expression response, to parasites and allergens, in several studies (69) , and although it is impossible, from whole lung microarray data, to determine which cell types are responsible for this increased expression, likely candidates would include airway epithelial cells, which are responsible for the goblet cell hyperplasia and mucus overproduction (2, 67) , which are defining features of the airway remodeling characteristic of asthma in both human patients (72) and mouse models (49) . Supporting this hypothesis, several of the most highly upregulated genes identified in our assay were involved Fig. 3 . Real-time RT-QPCR validation. Microarray results were validated by real-time RT-QPCR. We chose 14 genes with statistically significant change in expression following antigen challenge and/or RES treatment to represent approximately Ϫ20 to Ϫ2 and 2 to 20-fold changes in expression between antigen challenge and control animals (OVA vs. PBS) and between RES-treated and untreated animals (RES vs. OVA). The real-time RT-QPCR data of the 9 genes whose expression was both significantly higher in OVA than PBS A/J mice and significantly lower in RES than OVA A/J mice (based on the microarray data) is illustrated in A. The real-time RT-QPCR data of the 5 genes whose expression was significantly higher in RES than OVA mice is illustrated in B. All significant differences were confirmed by the real-time RT-QPCR data. *P Յ 0.05, **P Յ 0.01, ***P Յ 0.001; n ϭ 5 or 6 for each group.
with mucus production. In our study, the level of Clca3 RNA was found to be 20 times higher in OVA-challenged mice than in control animals. Clca3 has consistently been identified as one of the most highly upregulated genes in mouse models of asthma whether in response to OVA (44, 48, 100) , A. fumigatus (48, 100), or IL-13 (44, 48) . Furthermore, increased expression of CLCA1, the human ortholog of Clca3, has been observed in the airways of asthmatic patients where it is associated with mucus production (30, 88) . Clca3 expression is stimulated by the Th2 cytokines IL-4, IL-9, and IL-13 (99) , and it is expressed by goblet cells, where its protein product has been observed in mucin granules (47) . Expression of Muc5ac and Muc5b, the main gel-forming components of mucus (42, 73) , was also highly upregulated following OVA challenge and has been observed almost universally in previous studies (44, 48, 100) . Other than goblet cell hyperplasia, the remodeling associated with asthma is also characterized by an increase in ASM mass and subepithelial fibrosis. ASM mass increase is caused by hyperplasia and, possibly, hypertrophy of ASM cells (27) , while the subepithelial fibrosis is characterized by collagen deposition and alterations of the ECM. A weakness inherent in most mouse models of allergic asthma is that increases in ASM mass are not normally observed (49, 55) . While this was also the case with the model employed in the present study, a large number of genes associated with subepithelial fibrosis were significantly upregulated in the A/J strain.
The expression of coagulation factors 7 (F7) and 10 (F10), as well as tissue factor pathway inhibitor 2 (Tfpi2), which inhibits the activation of F10, were all consistently upregulated and may contribute to airway remodeling, and eventually airway hyperresponsiveness, through the production of fibrin (90) , or by other mechanisms (57) . As far as complement genes are concerned, the expression of C1qb, C1qc, and C3, as well as the complement 3a receptor 1 (C3ar1), was similarly found to be universally upregulated regardless of the asthma model used. Several mechanisms are known to induce C3 expression and lead to airway hyperresponsiveness, including the Th2 cytokines IL-4 (39) and IL-13 (43) and several airborne pollutants including diesel exhaust particles (37, 94) , ozone (68) , and cigarette smoke (71) . An important difference between the A/J and C57BL/6 mice is that the former harbors a mutation in the hemolytic complement (Hc or C5) gene that renders these mice C5 deficient. While there is evidence that this gene is involved in the differential asthma susceptibility of the A/J and C57BL/6 strains and that the balance of the C5a and C3a anaphylatoxins modulates the response to allergens during the sensitization phase (97) , the C5a protein is believed to have proinflammatory effects during the challenge phase. The use of intraperitoneally administered antigen combined with adjuvant appears to overcome the protective effect of C5a, as the C57BL/6 mice are efficiently sensitized against the antigen in ϩ and CD11b ϩ double-positive cells. Data were pooled from 2 independent experiments with a total n of 5-6; *P Յ 0.05, **P Յ 0.01, ***P Յ 0.001. our model as previously described (60) . Furthermore, we observed no modulation of Hc (C5) transcripts across any of the C57BL/6 experimental groups, suggesting that in the challenge phase of this model of allergic asthma, C5 status does not significantly affect outcome.
The most common receptors for the six chemokines that were consistently found to be upregulated across the different genome-wide expression studies were Ccr1, Ccr2, and Ccr3. While the Ccr1 receptor agonists include Ccl7 (MCP-3), Ccl8 (MCP-2), and Ccl9 (MIP-1␥) (6, 74) , there are at least eight other chemokines that can act as Ccr1 agonists. Given this high level of polygamy, it is not surprising that many of the chemokines found to be induced in experimental asthma, by genome-wide expression analyses, can act as agonists for this receptor. There is, however, a large body of evidence that implicates Ccr1 signaling in the pathogenesis of asthma, including the observed dependence on Ccr1 of respiratory syncytial virus-induced asthma exacerbations in a BALB/c model (32) , the protective effect of a Ccr1 antagonist in a mouse model of chronic asthma (12) , and elevated Ccr1 expression by ASM cells (34) and mast cells (3) in human asthma patients.
Most of the chemokines known to be Ccr2 agonists were found to be induced, following the induction of experimental asthma, in every genome-wide expression study, strongly suggesting that this receptor is involved in allergic asthma in mouse models. Ccr2 is the only known receptor for Ccl2 (MCP-1), and the presence of this chemokine is known to be able to induce the polarization of naive T cells toward the Th2 arm of adaptive immunity (22, 38) . Furthermore, a recent meta-analysis of microarray data from mouse asthma models has also identified Ccl2 as a central regulator of a gene expression module that includes many genes, such as Chia, Chi3l3, and Adam8, that are consistently activated in asthmatic mice (66) . The literature surrounding the role of Ccr2 in asthma is, however, quite contradictory, since studies in Ccr2 knockout mice have shown that deletion of Ccr2 had either no effect (53) on asthmatic phenotypes or that it resulted in increased airway responsiveness and eosinophilia and increased IgE production (41) . A study in primates, however, demonstrated that administration of a Ccr2 antagonist could prevent the development of asthma (58) .
Finally, Ccr3 is another chemokine receptor with a large number of known agonists. Of these, Ccl8 and Ccl11 (eotaxin) were consistently observed to be induced following the induction of experimental asthma and were found to be among the most highly upregulated genes in the present study [along with Ccl24, also known as eotaxin-2, which was not found to be significantly induced in the studies by Zimmerman et al. (100) or Kuperman et al. (44)]. Ccr3 is expressed by several types of cells implicated in asthma pathology including eosinophils (98) , mast cells (84) , and selectively by Th2 T cells (75) , and there is evidence that Ccr3 plays a role in the development of asthma in both mice (20, 95) and humans (46) .
The role of these consistently altered genes in the pathophysiology of experimentally induced allergic asthma in mice, or of allergic asthma in human patients, remains uncertain. However, there is strong evidence that at least several may contribute to disease development and progression.
Resiquimod treatment had a significant impact on transcription in the lungs of treated animals resulting in the altered expression of 386 genes in both A/J and C57BL/6 mice. Interestingly, resiquimod treatment resulted in similar numbers of up-and downregulated genes (215 and 171, respectively) whereas antigen challenge alone resulted almost exclusively in the upregulation of gene expression. The vast majority of genes that were identified as both altered following antigen challenge and following resiquimod treatment were upregulated following antigen challenge and downregulated following resiquimod treatment.
Genes whose expression was significantly altered following resiquimod treatment can be divided into two groups. The first is composed of those genes whose expression is normalized by resiquimod treatment, that is, those genes whose expression was induced following antigen challenge and whose expression was comparatively repressed after resiquimod treatment. The second category includes genes whose expression is specifi- Comparison of the of the number of genes whose expression was found to be significantly altered, by allergen challenge of sensitized mice, in the present study, in the BALB/c ovalbumin-and A. fumigatus-induced models used by cally altered by treatment and that were not initially upregulated following asthma induction. Of the 197 genes whose expression was altered by antigen challenge, the expression of 55 (or 28%) was normalized by resiquimod treatment. However, most of the genes (83%) whose expression was affected by resiquimod treatment were not affected by antigen challenge alone.
Of the 12 chemokines whose expression was upregulated following antigen challenge, the expression of six [Ccl8, Ccl11, Ccl12 (MCP-5), Ccl17 (TARC), Ccl24, and Cxcl12 (SDF)] was normalized following resiquimod treatment. Of the six remaining chemokines, the expression of five was not significantly altered in the treated versus untreated animals, and the expression of one, Cxcl9, was induced by antigen challenge and further induced by resiquimod treatment. Most of the downregulated chemokines were Ccr2 or Ccr3 agonists, except for the Th2 chemokines Ccl17 and Ccl22 (MDC), which bind Ccr4.
The expression of several genes that were highly upregulated following antigen challenge, such as Ear11 or Slc26a4, as well as genes whose expression was consistently altered across different microarray studies (44, 100) , such as Chia, Agr2, or Scin, were normalized by resiquimod treatment. However, the 55 genes whose expression was normalized by resiquimod treatment represent only 14% of the 387 genes whose expression was altered by resiquimod treatment. Furthermore, these 55 genes represent 85% of the 65 genes whose expression was altered both by antigen challenge and resiquimod treatment.
Interestingly, none of the complement cascade genes whose expression was induced by antigen challenge were normalized by resiquimod treatment, and the expression of a few of these genes, including those for complement factor B (Cfb) and the C1q ␤ polypeptide (C1qb), as well as the gene for the C3a receptor (C3ar1), was further induced by resiquimod treatment. Despite the consistency with which coagulation and complement cascade genes were identified in genome-wide expression studies, and the literature addressing the role of these factors in asthma (43, 57) , these findings suggest that expression of complement cascade genes, while strongly associated with and possibly functionally implicated in the development of experimental asthma pathology in mouse models, is not sufficient for the development of this pathology.
While resiquimod treatment led to the suppression of several chemokines that were upregulated by antigen challenge, it also induced the expression of others. The expression of the C-C motif chemokines Ccl3 (MIP-1␣) and Ccl5 (RANTES) and the C-X-C motif chemokines Cxcl9 (MIG) and Cxcl13 (BLC, BCA-1) was induced in the lungs of resiquimod-treated animals. Ccl3 has been shown to induce Th1 differentiation of naive T cells in the presence of antigen (38) , while Cxcr3, the Cxcl9 receptor, is preferentially expressed on Th1 cells (40) . These findings are consistent with the known immunomodulatory activities of resiquimod (89) and studies in which resiquimod was used in a mouse model of allergic asthma (70, 78) , although the latter finding was not observed in all studies (60) . Furthermore, in vitro microarray analysis of purified plasmacytoid dendritic cells also found that several chemokines and chemokine receptors were induced by resiquimod treatment. In particular, Ccl3, Ccl5, Cxcl9, and the Ccr5 and Cxcr3 receptors were found to be induced in isolated dendritic cells (7) , suggesting that this cell type is at least partially responsible for the chemokine production observed in our model.
In contrast to the large number of chemokines that were affected by resiquimod treatment, the expression of relatively few other cytokines, including only a single interleukin, was significantly altered. The single interleukin, IL-16, was significantly induced by resiquimod treatment. This cytokine is known to be chemotactic for Cd4 ϩ Ccr5 ϩ double-positive cells. Because Ccr5 is preferentially expressed on Th1 cells, IL-16 preferentially induces migratory responses in Th1 cells compared with Th2 cells (52) . The expression of several cytokine receptor genes, including the interleukin receptor genes IL2rb, IL3ra, IL10ra, IL17ra, and IL22ra, the interleukin 18 receptor-associated protein IL18rap, and the tumor necrosis subfamily receptor genes Tnfrsf13b and Tnfrsf13c, however, was induced by resiquimod treatment.
Many genes associated with B cells were altered by resiquimod treatment. The cytokine Tnfsf1b (BAFF) signals through Tnfrsf13b (TACI) (81) and Tnfrsf13c (BAFFR) (76, 87) , both of which are expressed on B cells, the latter being necessary for B cell survival. The expression of both receptors was induced by resiquimod treatment. A dichotomy exists, however, for B cell receptor (BCR) signaling. Cd72 is an inhibitor of BCR signaling (65, 93) and induced by resiquimod treatment. On the other hand, Cd79a and Cd79b, genes that encode components of the BCR complex, as well as several genes involved in BCR signaling, including Blnk, Rac2, and Vav1, were also induced by resiquimod treatment. It is possible that the induction of inhibitory genes and the suppression of receptors necessary for B cell survival were part of a negative feedback mechanism as resiquimod has been shown to be a potent mediator of B cell activation (8) .
Among other genes related to immunity, resiquimod treatment also induced the expression of a number of cell adhesion molecules, including integrins, cadherins, and selectins, several histocompatibility-2 genes, as well as a large number of genes associated with NK cells, or involved in NK cell-mediated cytotoxicity. The number of transcripts of both NK cell receptors, including Ncr1 (Nkp46) and a number of killer cell lectin-like receptors (Klra2, Klra3, Klra8, Klrc1, Klrd1, and Klrk1), as well as several genes involved in NK cell-mediated cytotoxicity such as perforin (Prf1), Fas ligand (Fasl), and granzymes (Gzma, Gzmb), was much higher in the lungs of resiquimod-treated animals.
Since it is known that resiquimod can lead to both the activation of NK cells and enhancement of NK cell-mediated cytotoxicity, at least in vitro (21, 24) , we determined whether the increased expression of NK cell-associated genes was due to the recruitment of NK cells into the lungs of the treated mice. By flow cytometry we found that the lungs of resiquimod-treated animals did indeed contain elevated levels of NK cells and that these levels were sustained for at least 48 h. Furthermore, NK cell recruitment, when resiquimod is administered systemically by intraperitoneal injection, was not limited to the lungs as it was also observed in the liver. Employing anti-NK1.1 antibodies we demonstrated that that NK cells were not required in order for resiquimod to prevent the development of experimental allergic asthma in mice. Similarly, using Cd8 knockout mice, we demonstrated that resiquimod treatment does not depend on Cd8-positive T cells.
The majority of the morbidity and mortality associated with asthma are caused by exacerbations, and as many as 85% of these exacerbations are associated with viral infections (33, 64) . As present therapies are only moderately effective at preventing asthma exacerbations, new approaches are needed (85) . Through IFN-␥ production and the lysis of infected cells, NK cells are important in the control of viral infections (50) . Due to its ability to inhibit the development of asthma pathology and to recruit NK cells to the lungs for several days and the known antiviral activities of the imidazoquinoline family of compounds, resiquimod represents a promising new approach for the prevention and treatment of asthma exacerbations that warrants further investigation.
In summary we have shown that there is a common set of genes that are induced following antigen challenge in the mouse models of allergic asthma currently in use. In particular, groups of genes that are reproducibly and significantly upregulated include genes involved in the control of cell cycle progression, the complement and coagulation cascades, and chemokine signaling. Moreover, there were several genes of uncertain function that were consistently found to be highly induced. We have shown that resiquimod treatment, which completely inhibits the development of experimental allergic asthma, had wide ranging effects on the transcriptional environment of the lung. While resiquimod treatment normalized the expression of genes involved in airway remodeling and, for the most part, chemokine signaling, it also induced the expression of a number of genes involved in a variety of immunological processes. Furthermore, systemic administration of resiquimod resulted in the recruitment of a large number of NK cells to the lungs and liver, but not to the spleen. While the NK cell recruitment was dispensable in the context of asthma therapy per se, the relatively strong and sustained increase in pulmonary NK cell levels may be beneficial in the treatment of a multitude of viral respiratory infections, particularly in the context of preventing or treating asthma exacerbations.
